Added benefits of drospirenone for compliance

  title={Added benefits of drospirenone for compliance},
  author={Jean-Michel Foidart},
  pages={28 - 34}
  • J. Foidart
  • Published 1 January 2005
  • Medicine, Biology
  • Climacteric
Drospirenone is a novel progestogen that possesses antimineralocorticoid activity. This activity is seen clinically in its effects on physiological parameters, body weight, general well-being and fluid-related symptoms. Clinical studies with an oral contraceptive containing 30 μg ethinylestradiol and 3 mg drospirenone (Yasmin®, Schering AG, Berlin, Germany) and a new continuous combined oral hormone replacement therapy (HRT) containing 1 mg 17β-estradiol and 2 mg drospirenone (Angeliq… 

Safety, efficacy, actions, and patient acceptability of drospirenone/ethinyl estradiol contraceptive pills in the treatment of premenstrual dysphoric disorder

Additional large randomized placebo-controlled trials are needed to confirm the efficacy of the drospirenone OCs in the treatment of PMDD, but this OC formulation appears to be a promising therapeutic modality.

Drospirenone: a novel progestin

Drospirenone-containing contraceptives have similar efficacy and safety profiles to other low-dose oral contraceptives, but seem to offer improved tolerability with regard to weight gain, mood changes, acne and treatment of a severe form of premenstrual syndrome called pre menstrual dysphoric disorder.

Combination of Drospirenone and Estradiol: A New Hormone Therapy in Postmenopausal Women

  • J. Huber
  • Biology, Medicine
    Women's health
  • 2007
The problems that arise in connection with the menopause have been treated for many years with various hormone-replacement therapy formulations. The spironolactone derivative drospirenone is a novel

Drospirenone, a progestin with a unique cardiovascular profile, for safe contraception and treatment of menopausal symptoms

  • O. Ylikorkala
  • Medicine
    Climacteric : the journal of the International Menopause Society
  • 2005
A novel progestin is introduced, drospirenone, to be used in combination with ethinylestradiol for oral contraception or with estradiol with potentially harmful side-effects which are potentially harmful and reduce the tolerability of the contraceptive pill or HT.

Drospirenone/Ethinylestradiol 3mg/20µg (24/4 Day Regimen)

Clinical trials indicate that drospirenone/ethinylestradiol 3mg/20µg (24/4) is a good long-term contraceptive option, and additionally offers relief of symptoms that characterise PMDD and has a favourable effect on moderate acne vulgaris.

Evaluating the Cognitive Impacts of Drospirenone, a Spironolactone-Derived Progestin, Independently and in Combination With Ethinyl Estradiol in Ovariectomized Adult Rats

Drospirenone, a spironolactone-derived progestin, is investigated, which has unique pharmacological properties compared to other clinically-available progestins and natural progesterone, for its impact on spatial memory, anxiety-like behavior, and brain regions crucial to these cognitive tasks.

Estetrol combined with drospirenone: an oral contraceptive with high acceptability, user satisfaction, well-being and favourable body weight control

The present study shows that 15 mg estetrol combined with 3”mg DRSP is associated with a high-user acceptability and satisfaction, and with a favourable body weight control.

Profile of estetrol, a promising native estrogen for oral contraception and the relief of climacteric symptoms of menopause

A narrative review discusses E4’s pharmacological characteristics, mode of action, and the results of preclinical and clinical studies for contraception, as well as for menopause and oncology.



The contraceptive profile of a new oral contraceptive with antimineralocorticoid and antiandrogenic effects.

  • J. Foidart
  • Medicine, Biology
    The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception
  • 2000
Two large, randomized, multicenter, open-label clinical studies show that ethinylestradiol/drospirenone provides effective oral contraception, excellent cycle control and good tolerability, with effects on body weight and skin condition that are likely to confer a significant beneficial effect on compliance, especially in women with a tendency to gain weight under oral contraceptives due to water retention.

Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone

  • J. HuberJ. Foidart R. Heithecker
  • Medicine
    The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception
  • 2000
The combination of 30 g ethinylestradiol/3 mg drospirenone provides effective oral contraception, excellent cycle control, good tolerability and a level of weight loss that may have a significant beneficial effect on compliance in women with a tendency to weight gain due to water retention.

Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms

  • D. ApterA. Borsos S. Kelly
  • Medicine
    The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception
  • 2003
3 mg drospirenone in combination with 30 μg ethinylestradiol has been shown to have a beneficial effect on psychological general well-being, as measured by thePGWBI, the first study on oral contraceptives which has used the PGWBI in this population.

Effect of an oral contraceptive containing ethinyl estradiol and drospirenone on premenstrual symptomatology and health-related quality of life.

Premenstrual symptomatology, as measured with the negative affect and water retention domains of the Moos Menstrual Distress Questionnaire (MDQ), significantly improved from baseline in all phases of the menstrual cycle.

Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial

The use of drospirenone combined with estradiol provides protection against endometrial hyperplasia, reduces endometrian bleeding with time, and relieves menopausal symptoms.

Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder.

The results of this study show a consistent trend in the reduction of symptoms that suggested a beneficial effect of DRSP/EE for the treatment of PMDD, despite limitations of the study design.

Evaluation of a unique oral contraceptive (Yasmin) in the management of premenstrual dysphoric disorder.

  • E. Freeman
  • Medicine, Psychology
    The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception
  • 2002
Preliminary results suggest the beneficial effect of DRSP/EE on PMDD and offer an alternative class of medication that also provides the range of benefits of oral contraception for women with PMDD.